VitaCig, Inc. Implements Best-In Class Testing, Quality Control, and Chain of Custody Standards
May 13 2014 - 8:35AM
VitaCig, Inc. an mCig, Inc. (OTCQB:MCIG) Company, is pleased to
announce that it has initiated the implementation of best-in class
testing, quality control, and chain of custody standards within the
VitaCig manufacturing process.
As of May 15, 2014, VitaCig products will be manufactured under
the following guidelines:
Metallic and Electronic Components – All metallic and electronic
components utilized in the production of the VitaCig will be
independently tested as per the compliance requirements of RoHS
(Restriction of Hazardous Substance Directive) and the European CE
Mark.
Vitamins, Phytonutrients, Liquid ingredients – Batches of
Vitamins, Phytonutrients, and any other liquid ingredients found in
the VitaCig will be independently tested by Intertek Group, PLC for
the following substances:
B-myrcene or D-limonene or eucalyptol (depending on respective
sample), ascorbic acid, alpha-tocopherol acetate, vitamin A
palmitate, vitamin B1, CoQ10, organophosphate pesticides, microbes,
cadmium, lead, nickel, arsenic, mercury, and aluminum.
Following the receipt of successful test results from Intertek,
VitaCig ingredients will be cleared for insertion. Each batch of
ingredients will be catalogued and labeled with both nutritional
values as well as an expiration date. This label will be annexed to
each individual VitaCig package utilizing the same manufacturing
technology that is used in the pharmaceutical and nutritional
supplement industry. Once packaged, VitaCig products will be
shipped to our newly leased temperature-controlled storage center
in Pennsylvania, USA where they will remain until order
fulfillment.
"Long before any FDA Proposals, our team was initiation a plan
for the implementation of standards for independent testing and
chain of custody for all VitaCig products. We view VitaCig not as
an electronic cigarette but as a medical delivery device. That is
why we must ensure that every ingredient found within the VitaCig
can be properly accounted for and independently tested for
potential hazardous compounds. Independent testing also provides
the added benefit of testing our vitamins and phytonutrients for
potency and efficacy." Said Paul Rosenberg, CEO of mCig, Inc.
"When deciding on potential lab partners we were presented with
several options. Most labs had lower testing standards, and were
less costly than Intertek. Ultimately, we chose Intertek Group PLC,
a multi-billion dollar company because we felt their reputation
within the pharmaceutical testing industry would demonstrate our
commitment to ingredient transparency which in turn would help
promote VitaCig products as best-in class nicotine-free electronic
cigarettes."
"With the implementation of these standards, we are truly
setting the bar in the industry and positioning VitaCig to be
distributed on a national scale not only in conventional
distribution points but higher value distribution points that
require nutritional values, chain of custody, and quality control
as part of inventory inclusion." Said Mark Linkhorst, CEO of
VitaCig, Inc.
"Since joining mCig and VitaCig, I have received many
questions regarding the efficiency of direct inhalation of
vitamins. In my view, the educated consumer is watching closely
with genuine intellectual curiosity. Based on my knowledge of how
the industry currently operates, the implementation of the
standards announced today will separate the VitaCig brand from all
others via transparency in ingredient labeling and objective
quality assurance. This will further assist in the educational
process for consumers who will start viewing VitaCig products in
the same light as other independently tested nutritional
supplements." Said Dr. Khary Bryan Chief Technical Officer of
VitaCig, Inc.
About mCig, Inc. mCig, Inc. (OTCQB:MCIG) is a technology company
focused on two long-term secular trends sweeping the globe: (1) The
decriminalization and legalization of marijuana for medicinal or
recreational purposes (2) The adoption of electronic vaporizing
cigarettes (commonly known as "eCigs") by the world's 1.2 Billion
smokers. The company manufactures and retails the mCig – the
world's most affordable vaporizer priced at only $10. Designed in
the USA – the mCig provides a superior smoking experience by
heating plant material, waxes, and oils delivering a smoother
inhalation experience. The company also owns Vapolution, Inc.
which manufactures and retails home-use vaporizers such as the
Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc.
the company manufactures and retails the VitaCig, a $2
nicotine-free eCig that delivers a water-vapor mixed with vitamins
and organic flavors. Through its wholly owned subsidiary, LiqCig,
Inc. the company is engaged in the development of the world's first
pre-packaged alcohol friendly eCig. See more at:
http://www.mCig.org/, www.Vapolution.com, www.VitaCig.org The
Company believes that a well regulated marijuana industry is
emerging as more states follow the lead of Washington and Colorado
in legalizing marijuana. A similar trend is developing within the
eCig industry following the first acquisition of an electronic
cigarette brand (Blucigs) by a traditional tobacco company
Lorillard Inc. for $135 million followed by another acquisition in
February 2014 by Altria Group Inc. of Green Smoke for $150 million.
Wells Fargo analyst Bonnie Herzog estimates that eCig sales may
rise from $1 Billion in 2013 to $10 billion over the next three
years. mCig, Inc. (OTCQB:MCIG) has positioned itself as a first
mover at the intersection of these two trends and hopes to create
shareholder value by making the mCig one of the leading choices for
electronic consumption of plant material. - See more at:
http://www.mcig.org/investors/investor-opportunity-subpage/ Safe
Harbor Statement Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but
are subject to a number of risks and uncertainties. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products based on its technology; the expected benefits
and efficacy of the Company's products and technology; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
and future product commercialization; and the Company's business,
research, product development, regulatory approval, marketing and
distribution plans and strategies.
CONTACT: Paul Rosenberg
CEO
(425)462-4219